- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.08. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | 148 | GlobeNewswire (Europe) | -- Executing IND-enabling activities for next-generation PI3Ka pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027... ► Artikel lesen | |
| 04.08. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.07. | OnKure Aktie: H.C. Wainwright senkt Kursziel nach Neubewertung auf 21 US-Dollar | - | Investing.com Deutsch | ||
| 21.07. | H.C. Wainwright cuts OnKure stock price target to $21 on valuation changes | 3 | Investing.com | ||
| 02.07. | OnKure Therapeutics, Inc.: OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Ka Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 | 2 | GlobeNewswire (USA) | ||
| 05.06. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 04.06. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.05. | OnKure Therapeutics GAAP EPS of -$1.11 misses by $0.37 | 4 | Seeking Alpha | ||
| 30.03. | Leerink cuts OnKure stock price target on strategic shift | 2 | Investing.com | ||
| 30.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Oppenheimer reiterates OnKure stock rating on pipeline shift | 1 | Investing.com | ||
| 27.03. | OnKure Therapeutics prices $150M oversubscribed private placement | 1 | Seeking Alpha | ||
| 27.03. | OnKure raises $150M to advance breast cancer programs | 1 | Investing.com | ||
| 06.11.25 | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update | 328 | GlobeNewswire (Europe) | -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,870 | -0,33 % | IP Group: NAV Reaches £1 Billion As Pfizer Obesity Royalty Value Rises To £152 Million | ||
| INNOCAN PHARMA | 1,450 | -1,69 % | Innocan Pharma: Warum frisches Kapital jetzt zählt | ||
| VIATRIS | 14,848 | +0,11 % | Piper Sandler raises Viatris stock price target on patch growth | ||
| SYNBIOTIC | 0,851 | -0,12 % | Original-Research: SYNBIOTIC SE (von NuWays AG): Under review | Original-Research: SYNBIOTIC SE - from NuWays AG
24.08.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 22,500 | +1,35 % | Assembly Biosciences: Szenario 2030 - darum habe ich meine Position wieder erhöht | Nachdem die Aktie von Assembly Biosciences zwischen Anfang Juni und Anfang September zwischenzeitlich rund 70% an Wert gewonnen hatte, korrigierte sie in der vergangenen Woche um fast 20%. Vorausgegangen... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 58,76 | +0,07 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 10,170 | -0,83 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA | New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,995 | 0,00 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,150 | -0,49 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| OPKO HEALTH | 1,350 | -4,26 % | OPKO Health: Strategiewechsel hin zu Therapeutika, gestützt durch hohe Liquidität | ||
| JAGUAR HEALTH | 0,233 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenDE000A2YNT30 Alzchem Group AG 16.09.2026 DE000A41YHG1 Alzchem Group AG 17.09.2026 Tausch 1:1AU0000090060 Europa Metals... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,558 | -2,09 % | XORTX Therapeutics Inc.: XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO | ? Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ? CALGARY, Alberta, Sept. 10, 2026 (GLOBE... ► Artikel lesen | |
| OPUS GENETICS | 4,700 | -0,84 % | Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified? | ||
| SOLIGENIX | 0,360 | 0,00 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| TALPHERA | 1,010 | -3,81 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen |
ONKURE THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -0,52 % bei einem Aktienkurs von 2,865 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.